2023
Journal Articles- Refereed
JA Soon, YH To, M Alexander, K Trapani, PA Ascierto, S Athan, MP Brown, ... F Franchini, M IJzerman. A tailored approach to horizon scanning for cancer medicines. Journal of Cancer Policy 38, 100441
JA Soon, F Franchini, M Ijzerman, GA McArthur. The role of systemic therapies in current and emerging opportunities for de-intensification in melanoma: a scoping review protocol. medRxiv, 2023.11. 21.23298799
P Gillett, RK Mahar, NR Tran, M Rosenthal, M IJzerman. Developing and validating a multi-criteria decision analytic tool to assess the value of cancer clinical trials: evaluating cancer clinical trial value. Cost Effectiveness and Resource Allocation 21 (1), 87
F Franchini, V Fedyashov, MJ IJzerman, K Degeling. Implementing competing risks in discrete event simulation: the event-specific probabilities and distributions approach. Frontiers in Pharmacology 14, 1255021
A Drosdowsky, KE Lamb, A Karahalios, RJ Bergin, K Milley, L Boyd, MJ IJzerman, JD Emery. The effect of time before diagnosis and treatment on colorectal cancer outcomes: systematic review and dose–response meta-analysis. British journal of cancer 129 (6), 993-1006
M Fagery, HA Khorshidi, SQ Wong, M Vu, M IJzerman. Health economic evidence and modeling challenges for liquid biopsy assays in cancer management: a systematic literature review. PharmacoEconomics 41 (10), 1229-1248
A Drosdowsky, KE Lamb, RJ Bergin, L Boyd, K Milley, MJ IJzerman, ... A systematic review of methodological considerations in time to diagnosis and treatment in colorectal cancer research. Cancer epidemiology 83, 102323
S O’Haire, F Franchini, YJ Kang, J Steinberg, K Canfell, J Desai, S Fox, ... M IJzerman. Systematic review of NTRK 1/2/3 fusion prevalence pan-cancer and across solid tumours. Scientific reports 13 (1), 4116
A Pereira-Salgado, A Anton, F Franchini, RK Mahar, EM Kwan, S Wong, ... M IJzerman. Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents matters?. Expert Review of Pharmacoeconomics & Outcomes Research 23 (2), 231-239